Global Daptomycin Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2033

Daptomycin Market Size

• The global Daptomycin market size was valued at USD 4.86 billion in 2025 and is expected to reach USD 6.79 billion by 2033, at a CAGR of 4.27% during the forecast period
• The market growth is largely fueled by the rising prevalence of serious Gram-positive bacterial infections, including complicated skin and bloodstream infections, along with increasing hospital admissions and antibiotic resistance, which are driving greater demand for advanced antibiotic therapies such as daptomycin across both acute and critical care settings
• Furthermore, growing awareness among healthcare professionals about the clinical efficacy of daptomycin against multidrug-resistant pathogens, coupled with expanding use in hospital formularies and increasing investments in infectious disease treatment, is accelerating the uptake of daptomycin solutions, thereby significantly boosting the market’s growth

Daptomycin Market Analysis

• Daptomycin, a cyclic lipopeptide antibiotic used for the treatment of serious Gram-positive bacterial infections, is an increasingly vital therapeutic option in modern hospital and clinical settings due to its strong efficacy against multidrug-resistant pathogens such as MRSA and VRE, rapid bactericidal action, and favorable safety profile in complicated infections
• The escalating demand for daptomycin is primarily fueled by the rising global burden of hospital-acquired infections, increasing antibiotic resistance, and growing reliance on advanced injectable antibiotics for bloodstream infections, endocarditis, and complicated skin and soft tissue infections
• North America dominated the daptomycin market with the largest revenue share of approximately 38.6% in 2025, supported by high diagnosis rates of resistant infections, strong hospital infrastructure, widespread adoption of advanced antimicrobial therapies, and the presence of major pharmaceutical manufacturers, with the U.S. accounting for the majority of regional demand due to well-established treatment guidelines
• Asia-Pacific is expected to be the fastest-growing region in the daptomycin market during the forecast period, registering a CAGR of around 7.9%, driven by increasing healthcare expenditure, rising incidence of infectious diseases, expanding hospital networks, and improving access to advanced antibiotic therapies across countries such as China and India
• The Adult segment accounted for the largest market revenue share of 71.4% in 2025, driven by higher infection rates among adults, particularly elderly and immunocompromised populations

Report Scope and Daptomycin Market Segmentation

Daptomycin Market Trends

Increasing Focus on Advanced Antibiotic Therapies for Resistant Infections

• A significant and accelerating trend in the global daptomycin market is the growing emphasis on advanced antibiotic therapies to address the rising burden of multidrug-resistant gram-positive bacterial infections. Healthcare providers are increasingly prioritizing potent lipopeptide antibiotics such as daptomycin due to their effectiveness against serious infections caused by resistant pathogens
• For instance, in January 2024, several tertiary care hospitals in the U.S. and Europe expanded the clinical use of daptomycin for complicated skin and soft tissue infections (cSSTIs) and bacteremia caused by methicillin-resistant Staphylococcus aureus (MRSA). This reflects the growing clinical confidence in daptomycin-based treatment protocols
• The increasing preference for targeted antibiotic therapy over broad-spectrum antibiotics is reinforcing demand for daptomycin, as it minimizes unnecessary microbial exposure and helps slow antimicrobial resistance development
• Advancements in formulation stability and dosing regimens are further enhancing treatment adherence and therapeutic outcomes, supporting wider clinical adoption
• The rising use of daptomycin in hospital settings, particularly intensive care units (ICUs), underscores its role as a critical drug for severe, life-threatening infections
• This trend toward optimized and evidence-based antibiotic selection is strengthening the position of daptomycin as a cornerstone therapy in modern infectious disease management

Daptomycin Market Dynamics

Driver

Rising Incidence of Drug-Resistant Gram-Positive Infections

• The increasing prevalence of drug-resistant gram-positive bacterial infections worldwide is a major driver for growth in the Daptomycin market. Pathogens such as MRSA and vancomycin-resistant Enterococcus (VRE) are becoming more common in both hospital-acquired and community-acquired infections
  • For instance, in March 2025, the Centers for Disease Control and Prevention (CDC) reported a continued rise in antimicrobial-resistant infections in hospital settings, leading to greater reliance on last-line antibiotics such as daptomycin. This has significantly supported market demand
• Daptomycin’s rapid bactericidal activity and favorable safety profile make it a preferred option for treating complicated bloodstream infections and endocarditis
• The growing aging population and increasing rates of comorbidities such as diabetes and renal disorders further contribute to higher infection susceptibility, driving antibiotic demand
• Expanded clinical guidelines recommending daptomycin for specific resistant infections are also reinforcing its adoption across healthcare facilities
• Ongoing investments by pharmaceutical companies to expand production capacity and geographic availability are further accelerating market growth during the forecast period

Restraint/Challenge

High Treatment Costs and Risk of Resistance Development

• Despite strong demand, the Daptomycin market faces notable challenges related to the high cost of therapy, which can limit accessibility, particularly in low- and middle-income regions. The cost burden may restrict use to severe cases, reducing overall prescription volume
  • For instance, hospital pharmacoeconomic studies published in 2024 indicated that daptomycin treatment courses can be significantly more expensive than traditional antibiotic regimens, impacting formulary inclusion in cost-sensitive healthcare systems
• Prolonged or inappropriate use of daptomycin may also contribute to emerging resistance, raising concerns among clinicians regarding long-term efficacy
• The requirement for intravenous administration and close patient monitoring can further increase overall treatment costs and healthcare resource utilization
• Regulatory scrutiny and stringent approval pathways for antibiotic labeling expansions may delay market entry for new formulations or indications
• Addressing these challenges through antimicrobial stewardship programs, pricing optimization strategies, and ongoing clinical research will be essential to sustain long-term growth in the daptomycin market

Daptomycin Market Scope

The market is segmented on the basis of indication, age group, strength, and end user.

• By Indication

On the basis of indication, the Global Daptomycin market is segmented into Complicated Skin Structure Infections (cSSSI), Bacteremia, and Others. The Complicated Skin Structure Infections (cSSSI) segment dominated the largest market revenue share of 48.9% in 2025, driven by the high global prevalence of severe skin and soft tissue infections caused by Gram-positive pathogens, including MRSA. Daptomycin is widely prescribed for cSSSI due to its rapid bactericidal activity and effectiveness against resistant organisms. Hospitals and clinicians prefer daptomycin for patients who fail to respond to first-line antibiotics. Increasing hospital admissions for post-surgical infections and trauma-related wounds further support segment dominance. Favorable clinical outcomes and strong guideline support enhance adoption. Rising awareness of antimicrobial resistance strengthens reliance on advanced antibiotics such as daptomycin. These factors collectively position cSSSI as the leading indication segment.

The Bacteremia segment is expected to witness the fastest CAGR of 7.6% from 2026 to 2033, driven by the increasing incidence of bloodstream infections and sepsis caused by resistant Gram-positive bacteria. Daptomycin’s proven efficacy in treating Staphylococcus aureus bacteremia, including MRSA strains, fuels demand. Growing use in critical care settings and intensive care units supports rapid growth. Advancements in early diagnosis of bloodstream infections further expand treatment rates. Increasing awareness among clinicians regarding early aggressive antibiotic therapy contributes to adoption. Expanding approvals and guideline recommendations for bacteremia treatment strengthen market penetration. As hospital-acquired infections rise globally, this segment is expected to grow at a strong pace.

• By Age Group

On the basis of age group, the Global Daptomycin market is segmented into Paediatric and Adult. The Adult segment accounted for the largest market revenue share of 71.4% in 2025, driven by higher infection rates among adults, particularly elderly and immunocompromised populations. Adults are more susceptible to hospital-acquired infections, bacteremia, and complicated skin infections requiring advanced antibiotics. The rising prevalence of chronic diseases such as diabetes and renal disorders increases infection risk, driving demand for daptomycin. Higher hospitalization rates and longer treatment durations in adults further contribute to revenue dominance. In addition, most approved indications for daptomycin are primarily targeted toward adult patients. Strong physician familiarity and established dosing protocols support sustained adoption. These factors collectively reinforce adult dominance in the market.

The Paediatric segment is projected to register the fastest CAGR of 8.2% from 2026 to 2033, driven by increasing clinical studies supporting safe pediatric use and expanding off-label adoption. Rising incidence of resistant bacterial infections in pediatric populations is fueling demand. Improved diagnostic capabilities and growing awareness among pediatric infectious disease specialists contribute to growth. Regulatory advancements and pediatric-specific dosing guidelines further support adoption. Hospitals are increasingly using daptomycin for severe pediatric infections unresponsive to standard antibiotics. Expansion of pediatric healthcare infrastructure in emerging economies also boosts demand. These trends position pediatrics as the fastest-growing age group segment.

• By Strength

On the basis of strength, the Global Daptomycin market is segmented into 350 mg and 500 mg. The 500 mg segment dominated the largest market revenue share of 63.7% in 2025, driven by its widespread use in adult patients requiring higher therapeutic dosing. The 500 mg formulation is commonly preferred in hospital settings due to dosing convenience and reduced preparation time. It is particularly suitable for treating severe infections such as bacteremia and endocarditis. Hospitals favor higher-strength formulations to minimize vial usage and dosing errors. Increased use in critically ill patients further supports dominance. Strong availability across regions and standardized prescribing practices enhance adoption. As a result, the 500 mg segment remains the market leader.

The 350 mg segment is expected to witness the fastest CAGR of 6.9% from 2026 to 2033, driven by rising demand for flexible dosing, particularly in pediatric and lower-weight adult patients. The 350 mg strength allows better dose adjustment and reduced drug wastage. Increasing focus on personalized medicine and optimized antibiotic stewardship supports growth. Hospitals and clinics prefer lower-strength formulations for tailored treatment regimens. Expanding use in outpatient and step-down care settings further boosts adoption. These factors are expected to drive steady growth of the 350 mg segment globally.

• By End User

On the basis of end user, the Global Daptomycin market is segmented into Pharmaceuticals, Clinics, and Wellness Centers. The Pharmaceuticals segment held the largest market revenue share of 54.8% in 2025, driven by large-scale manufacturing, distribution, and supply of branded and generic daptomycin formulations. Pharmaceutical companies play a key role in ensuring global availability through hospital contracts and bulk supply agreements. Strong R&D investments, regulatory approvals, and production scalability contribute to dominance. The presence of multiple generic manufacturers further expands market reach. Strategic partnerships with healthcare providers enhance distribution efficiency. As demand for advanced antibiotics increases, pharmaceutical companies continue to lead revenue generation.

The Clinics segment is expected to register the fastest CAGR of 7.4% from 2026 to 2033, driven by rising outpatient treatment of bacterial infections and reduced hospital stays. Clinics are increasingly managing moderate infections with intravenous antibiotic administration. Growth in specialty infectious disease clinics supports adoption. Improved access to infusion services and monitoring capabilities further encourage clinic-based use. Cost containment efforts by healthcare systems favor treatment outside hospitals. These factors are accelerating daptomycin usage in clinical settings, making clinics the fastest-growing end-user segment.

Daptomycin Market Regional Analysis

• North America dominated the daptomycin market with the largest revenue share of approximately 38.6% in 2025, supported by high diagnosis rates of antibiotic-resistant infections, strong hospital and clinical infrastructure, and widespread adoption of advanced antimicrobial therapies. The region benefits from well-established treatment guidelines for serious Gram-positive infections and the strong presence of leading pharmaceutical manufacturers
• The region’s dominance is further reinforced by favorable reimbursement policies, high awareness among healthcare professionals regarding the clinical benefits of daptomycin, and increased use of the drug in treating complicated skin and soft tissue infections as well as bloodstream infections
• Continued investments in infectious disease management, antimicrobial stewardship programs, and hospital-based care are sustaining strong demand for daptomycin across both inpatient and specialized care settings in North America

U.S. Daptomycin Market Insight

The U.S. daptomycin market captured the largest revenue share within North America in 2025, driven by a high burden of methicillin-resistant Staphylococcus aureus (MRSA) and other resistant Gram-positive infections. The country’s advanced healthcare system, strong clinical research environment, and early adoption of novel antibiotic therapies support sustained market growth. Additionally, the presence of established pharmaceutical companies and robust hospital networks continues to propel demand for daptomycin in the U.S.

Europe Daptomycin Market Insight

The Europe daptomycin market is projected to expand at a steady CAGR during the forecast period, primarily driven by increasing antimicrobial resistance, rising hospitalization rates, and strong regulatory oversight promoting appropriate antibiotic use. Growing awareness of advanced lipopeptide antibiotics and expanding use in severe bacterial infections are supporting market expansion across the region.

U.K. Daptomycin Market Insight

The U.K. daptomycin market is anticipated to grow at a noteworthy CAGR, supported by national antimicrobial resistance strategies, strong public healthcare infrastructure, and increasing use of advanced antibiotics in hospital settings. The emphasis on evidence-based treatment protocols and infection control measures is contributing to steady adoption.

Germany Daptomycin Market Insight

The Germany daptomycin market is expected to expand at a considerable CAGR during the forecast period, driven by a strong hospital network, high healthcare spending, and increasing incidence of resistant bacterial infections. Germany’s focus on clinical innovation and strict antibiotic stewardship programs supports the controlled yet consistent growth of the daptomycin market.

Asia-Pacific Daptomycin Market Insight

The Asia-Pacific daptomycin market is expected to be the fastest-growing region, registering a CAGR of around 7.9% during the forecast period, driven by increasing healthcare expenditure, rising incidence of infectious diseases, and rapid expansion of hospital infrastructure. Improving access to advanced antibiotic therapies and growing awareness of resistant infections are accelerating adoption across the region.

Japan Daptomycin Market Insight

The Japan daptomycin market is gaining momentum due to an aging population, rising prevalence of hospital-acquired infections, and strong emphasis on effective antimicrobial treatment. Advanced healthcare infrastructure and growing use of novel antibiotics in severe infections are supporting steady market growth.

China Daptomycin Market Insight

The China daptomycin market accounted for the largest revenue share in Asia-Pacific in 2025, attributed to expanding hospital networks, rising infectious disease burden, and increasing government focus on improving access to advanced therapies. Growth is further supported by expanding pharmaceutical manufacturing capabilities and increasing adoption of advanced antibiotics in tertiary care hospitals.

Daptomycin Market Share

The Daptomycin industry is primarily led by well-established companies, including:

• Pfizer Inc. (U.S.)
• Merck & Co., Inc. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sun Pharmaceutical Industries Ltd. (India)
• Dr. Reddy’s Laboratories Ltd. (India)
• Aurobindo Pharma Ltd. (India)
• Cipla Ltd. (India)
• Fresenius Kabi (Germany)
• Sandoz (Switzerland)
• Hikma Pharmaceuticals PLC (U.K.)
• Lupin Limited (India)
• Zydus Lifesciences Ltd. (India)
• Accord Healthcare (U.K.)
• Baxter International Inc. (U.S.)

Latest Developments in Global Daptomycin Market

• In October 2021, Merck issued a voluntary nationwide recall of CUBICIN (daptomycin for injection 500 mg, Lot 934778) in the U.S. due to the presence of particulate matter (glass) identified in the vials, notifying customers and initiating returns to ensure patient safety
• In January 2023, Camber Pharmaceuticals’ generic daptomycin for injection products (350 mg and 500 mg vials) were launched, expanding access to cost-effective lipopeptide antibiotic options for treating complicated skin and skin structure infections in both adult and pediatric patients
• In November 2023, multiple FDA-approved daptomycin products were listed as available from various manufacturers — including Fresenius Kabi USA and Civica, Inc. — reflecting expansion of injectable daptomycin supply and portfolio offerings in the U.S. healthcare market
• In November 2024, Maia Pharms Inc. received FDA approval for its daptomycin for injection (350 mg and 500 mg), reinforcing competitive manufacturing and availability of this essential antibiotic in treatment protocols
• In March 2025, the CUBICIN RF (daptomycin 500 mg/10 mL) formulation was identified with updated FDA information, confirming its continued indication for complicated skin and skin structure infections and bloodstream infections, supporting therapeutic confidence and ongoing use in clinical practice

SKU-58637